1. Home
  2. VSXY vs LQDA Comparison

VSXY vs LQDA Comparison

Compare VSXY & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSXY

Victorias Secret & Co. Common Stock

N/A

Current Price

$88.68

Market Cap

6.3B

ML Signal

N/A

LQDA

Liquidia Corporation

HOLD

Current Price

$84.11

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSXY
LQDA
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
VSXY
LQDA
Price
$88.68
$84.11
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$41.00
AVG Volume (30 Days)
1.6M
1.4M
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.81
EPS
N/A
0.52
Revenue
N/A
$158,320,000.00
Revenue This Year
N/A
$278.87
Revenue Next Year
N/A
$57.13
P/E Ratio
N/A
$167.10
Revenue Growth
N/A
1031.18
52 Week Low
$74.60
$17.82
52 Week High
$91.97
$91.10

Technical Indicators

Market Signals
Indicator
VSXY
LQDA
Relative Strength Index (RSI) 59.98 59.67
Support Level $80.61 $70.28
Resistance Level $89.29 $91.10
Average True Range (ATR) 4.04 5.47
MACD 0.62 -0.02
Stochastic Oscillator 77.67 71.85

Price Performance

Historical Comparison
VSXY
LQDA

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: